PharVision Advisers’s RXO RXO Stock Holding History

PharVision Advisers’s Portfolio RXO Stock Details RXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,201	Closed	-$203K	–	966
2025 Q3	$203K	Buy	+13,201	New	+$213K	0.11%	504

Other funds holding RXO

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

PharVision Advisers's RXO Position: Q4 2025 in Review

PharVision Advisers sold out of RXO (RXO) in Q4 2025, closing a stake of 13,201 shares — an estimated $203K sold.

PharVision Advisers first reported a position in RXO in Q3 2025 and held it in 1 quarter. The position peaked at $203K in Q3 2025. 269 funds tracked by Wall St. Rank hold RXO as of Q4 2025.

PharVision Advisers reported no remaining RXO position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 13,201 RXO shares in Q4 2025, an estimated $203K.
PharVision Advisers first reported a position in RXO in Q3 2025 and held it in 1 quarter.
PharVision Advisers's RXO position peaked at $203K in Q3 2025.
269 funds tracked by Wall St. Rank held RXO as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.